Sucralfate: Difference between revisions
Elcatracho (talk | contribs) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: Carafate ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug...") |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: | ||
*Dosage Forms: | *Dosage Forms: suspension, tablet | ||
*Routes of Administration: | *Routes of Administration: PO | ||
*Common Trade Names: Carafate | *Common Trade Names: Carafate | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[Duodenal ulcer]] | |||
**Active ulcer treatment: 1g PO 4 times daily x 4-8 weeks | |||
**Maintenance therapy: 1g twice daily | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*[[Peptic ulcer disease]]: 40-80 mg/kg/day divided q6 hours, maximum 1000mg/dose | |||
*Esophagitis | |||
**3 months-6 years of age: 500mg PO 4 times daily | |||
**>6 years: 1000mg/dose four times daily | |||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *B: Acceptable for use in pregnancy | ||
===Lactation risk=== | ===Lactation risk=== | ||
* | *Use considered acceptable | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
* | *Use caution in chronic renal failure or dialysis due to absorption of aluminum salts | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
* | *No adjustment | ||
==Contraindications== | ==Contraindications== | ||
| Line 31: | Line 34: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Anaphylaxis | |||
*Bronchospasm, laryngeal/pharyngeal/pulmonary edema | |||
===Common=== | ===Common=== | ||
*Constipation | |||
==Pharmacology== | ==Pharmacology== | ||
Acts locally in GI tract, minimally absorbed | |||
*Half-life: | *Half-life: | ||
*Metabolism: | *Metabolism: none | ||
*Excretion: | *Excretion: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Binds to form complex with positively charged proteins in exudates, forming a viscous paste-like adhesive substance, which then selectively forms a protective coating that protects gastric lining against peptic acid, pepsin, and bile salts | |||
==Comments== | ==Comments== | ||
| Line 48: | Line 53: | ||
==See Also== | ==See Also== | ||
*[[peptic ulcer disease]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Uptodate | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 05:47, 21 April 2021
Administration
- Type:
- Dosage Forms: suspension, tablet
- Routes of Administration: PO
- Common Trade Names: Carafate
Adult Dosing
- Duodenal ulcer
- Active ulcer treatment: 1g PO 4 times daily x 4-8 weeks
- Maintenance therapy: 1g twice daily
Pediatric Dosing
- Peptic ulcer disease: 40-80 mg/kg/day divided q6 hours, maximum 1000mg/dose
- Esophagitis
- 3 months-6 years of age: 500mg PO 4 times daily
- >6 years: 1000mg/dose four times daily
Special Populations
Pregnancy Rating
- B: Acceptable for use in pregnancy
Lactation risk
- Use considered acceptable
Renal Dosing
- Use caution in chronic renal failure or dialysis due to absorption of aluminum salts
Hepatic Dosing
- No adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis
- Bronchospasm, laryngeal/pharyngeal/pulmonary edema
Common
- Constipation
Pharmacology
Acts locally in GI tract, minimally absorbed
- Half-life:
- Metabolism: none
- Excretion:
Mechanism of Action
- Binds to form complex with positively charged proteins in exudates, forming a viscous paste-like adhesive substance, which then selectively forms a protective coating that protects gastric lining against peptic acid, pepsin, and bile salts
Comments
See Also
References
Uptodate